Original Article
Single-Dose Perinatal Nevirapine plus Standard Zidovudine to Prevent Mother-to-Child Transmission of HIV-1 in Thailand
N Engl J Med 2004; 351:217-228July 15, 2004
- Abstract
Background
Although zidovudine prophylaxis decreases the rate of transmission of the human immunodeficiency virus (HIV) type 1 substantially, a large number of infants still become infected. We hypothesized that the administration, in addition to zidovudine, of a single dose of oral nevirapine to mothers during labor and to neonates would further reduce transmission of HIV.
Methods
We conducted a randomized, double-blind trial of three treatment regimens in Thai women who were receiving zidovudine therapy during the third trimester of pregnancy. In one group, mothers and infants received a single dose of nevirapine (nevirapine–nevirapine regimen); in another, mothers and infants received nevirapine and placebo, respectively (nevirapine–placebo regimen); and in the last, mothers and infants received placebo (placebo–placebo regimen). The infants also received one week of zidovudine therapy and were formula-fed. The end point of the study was infection with HIV in the infants, established by virologic testing.
Results
Between January 15, 2001, and February 28, 2003, a total of 1844 Thai women were enrolled. At the first interim analysis, the independent data monitoring committee stopped enrollment in the placebo–placebo group. Among women who delivered before the interim analysis, the as-randomized Kaplan–Meier estimates of the transmission rates were 1.1 percent (95 percent confidence interval, 0.3 to 2.2) in the nevirapine–nevirapine group and 6.3 percent (95 percent confidence interval, 3.8 to 8.9) in the placebo–placebo group (P<0.001). The final per-protocol transmission rate in the nevirapine–nevirapine group, 1.9 percent (95 percent confidence interval, 0.9 to 3.0), was not significantly inferior to the rate in the nevirapine–placebo group (2.8 percent; 95 percent confidence interval, 1.5 to 4.1). Nevirapine had an effect within subgroups defined by known risk factors such as viral load and CD4 count. No serious adverse effects were associated with nevirapine therapy.
Conclusions
A single dose of nevirapine to the mother, with or without a dose of nevirapine to the infant, added to oral zidovudine prophylaxis starting at 28 weeks' gestation, is highly effective in reducing mother-to-child transmission of HIV.
Media in This Article
Figure 1
Treatment Assignment, Loss to Follow-up, and Outcome of Pregnancy.Table 1
Characteristics of Mothers, Deliveries, and Infants in the Study, According to the Treatment Assignment.Article Activity
- Article
Mother-to-child transmission of the human immunodeficiency virus (HIV) remains a major health problem worldwide, even though the preventive efficacy of zidovudine was established in 1994.1-3 In Thailand, where 1.3 percent of pregnant women are infected with HIV, since 1993 the Ministry of Public Health has operated programs for voluntary counseling and testing of pregnant women and has provided free infant formula to mothers infected with HIV.4 Since 1999, this national program has provided zidovudine therapy during the last trimester of pregnancy, at delivery, and to the newborn. Even with these interventions, however, transmission rates remain at or above 6 percent.5,6 When a clinical trial demonstrated the efficacy of a single dose of nevirapine (Viramune, Boehringer Ingelheim) during labor plus a single dose to the newborn,7 we hypothesized that, without additional toxicity, logistic complications, or significant cost, perinatal nevirapine therapy added to zidovudine therapy could further reduce mother-to-child transmission of HIV in Thailand.
Methods
Trial Design
We conducted a multicenter, phase 3, double-blind, randomized, placebo-controlled trial. The primary objective was to assess the safety and efficacy of a single dose of nevirapine administered to women at the onset of labor and given to infants between 48 and 72 hours after birth, added to zidovudine prophylaxis, for the prevention of mother-to-child transmission of HIV type 1. A secondary objective was to evaluate the incremental effect of the administration of perinatal nevirapine to newborns.
The ethics committees of the Thai Ministry of Public Health, Chiang Mai University, and the Harvard School of Public Health approved the protocol used in the study, including the amendments. All study sites complied with regulations of the Department of Health and Human Services for the protection of human research subjects.
Patients
Eligible subjects were pregnant women participating in the national program of voluntary counseling and testing who were receiving zidovudine prophylaxis (starting at 28 weeks' gestation or as soon as possible thereafter) at any of 37 study sites in Thailand. The subjects were enrolled between January 15, 2001, and February 28, 2003. Pre-enrollment evaluations included HIV testing; history taking and physical examination; ultrasonographic uterine imaging; measurement of hemoglobin, white-cell and differential counts; CD4 count; measurements of plasma HIV RNA, alanine aminotransferase, and creatinine; and hepatitis B surface antigen and hepatitis C virus serologic testing.
The subjects were randomly assigned to one of three study groups at enrollment if they had received zidovudine for at least 2 weeks, had provided written informed consent, agreed not to breast-feed, and had the following laboratory values within 21 days before randomization: hemoglobin level greater than 8.0 g per deciliter, absolute neutrophil count greater than 750 cells per cubic millimeter, alanine aminotransferase level less than five times the upper limit of normal (i.e., less than 35 U per liter), and creatinine level less than 1.5 mg per deciliter (132.6 μmol per liter). Exclusion criteria included a maternal or fetal condition or a concomitant treatment that contraindicated treatment with zidovudine or nevirapine, oligohydramnios, unexplained polyhydramnios or in utero anemia, or a medical condition that required immediate use of highly active antiretroviral therapy. Open-label nevirapine was available to women who did not enroll in the study.
Until delivery, the women in the study had an obstetrical examination every two weeks; every other week, blood was drawn for hematologic, virologic, and biochemical testing. Adherence to zidovudine therapy was assessed at each visit by counting pills. After delivery, the women were seen at 10 days, 6 weeks, and 4 months for a physical examination and for hematologic and virologic monitoring. They were referred to an internist for further follow-up.
Infants were examined at birth, and follow-up visits were scheduled at 10 days (for measurement of hematocrit and alanine aminotransferase levels), 6 weeks (for hematologic tests), and 4, 6, 9, and 12 months. At each visit, a supply of powdered formula was provided to the mother; the child's health history since the previous visit was recorded, including the measurement of weight, recumbent length, and head circumference; and a clinical examination of the infant was performed. To determine the presence or absence of HIV infection, peripheral blood obtained at birth, six weeks, and four and six months was spotted onto filter papers, dried, and stored at –20°C to await shipping to the New England Newborn Screening Program for testing with a polymerase-chain-reaction (PCR) DNA assay for HIV (Amplicor HIV-1 DNA, version 1.5, Roche Molecular Systems).5 Serious adverse events were reported to the ministry of public health and Boehringer Ingelheim.
All the women received 300 mg of zidovudine twice daily starting at 28 weeks' gestation or as soon as possible thereafter; the dosing regimen was changed to 300 mg every three hours from the onset of labor until delivery. Infants received 2 mg of zidovudine per kilogram of body weight in an oral suspension every six hours for one week after birth. In accordance with national guidelines, if the mother had received zidovudine for a period of less than four weeks, the infant was treated for four to six weeks.8
Prophylaxis against opportunistic infections was provided as necessary, including the administration of oral trimethoprim–sulfamethoxazole to immunocompromised women9 and to infants from six weeks of age until it was established that they were not infected.10 After delivery, immunocompromised women and HIV-infected, immunocompromised infants were offered antiretroviral treatment that was provided by the Ministry of Public Health.8
Treatment
Women were randomly assigned to one of three treatment groups. In the nevirapine–nevirapine group, women received one dose of oral nevirapine (200 mg) at the onset of labor and neonates received nevirapine oral suspension (6-mg fixed dose, 0.6 ml) between 48 and 72 hours after birth. In the placebo–placebo group, women received placebo at the onset of labor and neonates received placebo between 48 and 72 hours after birth. In the nevirapine–placebo group, women received one dose of oral nevirapine (200 mg) at the onset of labor and neonates received placebo between 48 and 72 hours after birth.
In instances of prolonged and false labor, additional doses were provided to women every 48 hours until delivery. Infants born less than one hour after the mother had ingested nevirapine or placebo while in labor, according to the random assignment of treatment, were to be given the assigned treatment within six hours after birth.
Randomization and Blinding
On enrollment, women were provided with the study drug, either nevirapine or matched placebo, to be taken at home at the onset of labor. The study drugs were identified by random numbers with the use of permuted blocks of six in a ratio of 1:1:1. Twins were assigned to receive the same study drug. Additional doses were accessible in a blinded fashion at any hospital participating in the study with the use of a shared code. The study drugs were provided by Boehringer Ingelheim and were repackaged at the pharmacy of Children's Hospital, Boston, in individual blisters or oral syringes (Exacta-Med dispenser, Baxa).
Primary End Point
Infants were considered to be infected with HIV if the results of the PCR test were positive in blood obtained on two separate occasions, and infants were considered to be uninfected if the test results were negative on two occasions after one month of age.11 Infants who did not meet this definition were evaluated and classified as infected (six infants) or uninfected (three infants) by a clinician and a virologist before unblinding. In twins, infection in one or both was counted as one transmission.
Statistical Analysis
The study was designed primarily to test the superiority of the nevirapine–nevirapine regimen over the placebo–placebo regimen. We calculated that 484 mother–infant pairs were needed in each treatment group for a 0.05 one-sided type I error with 0.8 power, assuming a transmission rate of 8 percent in the placebo–placebo group and 4 percent in the nevirapine–nevirapine group. The nevirapine–placebo group was added in order to estimate, as a secondary objective, the proportion of overall transmission that was prevented by treating infants with nevirapine. Assuming that 5 percent of the cases could not be evaluated, the initial target sample size was 1530.
Interim safety analyses were planned when 40 percent and 70 percent of the total number of women had been enrolled. An increased rate of transmission associated with any of the three treatment regimens would be considered significant if any nominal P value was less than 0.0004 at the first interim analysis (with the use of O'Brien–Fleming boundaries as modified by Lan and DeMets and the use of one-sided tests with Bonferroni adjustments for multiple comparisons).12-14
After the first interim analysis, on May 2, 2002, the independent data and safety monitoring committee recommended stopping enrollment in the placebo–placebo group. The trial design was modified, and the target sample size was increased to 695 per treatment group to ensure 0.8 power to test for noninferiority of the nevirapine–placebo regimen as compared with the nevirapine–nevirapine regimen. Noninferiority would be declared if the upper limit of the 95 percent one-sided confidence interval of the observed difference was lower than 2.5 percent.
Two separate efficacy analyses were performed. The first efficacy analysis included all three treatment groups and all mothers who delivered before the first interim analysis. The second tested the noninferiority of the nevirapine–placebo regimen as compared with the nevirapine–nevirapine regimen. In addition to an as-randomized analysis, a per-protocol analysis was performed, primarily to test for noninferiority, in which the populations compared were defined according to actual intake of the assigned study drug, major deviations from the protocol, and adherence to zidovudine prophylaxis.15 Infants were analyzed according to the actual intake of the maternal or infant study drug. For the per-protocol analysis, criteria for exclusion were the intake of placebo by the mother and nevirapine by the infant, an infant's receipt of nevirapine more than 72 hours after birth or more than 6 hours after birth if the mother delivered less than 1 hour after receiving nevirapine, undocumented timing of intake by the mother or infant of the study drug, intake by the mother of the study drug more than 96 hours before delivery, less than 50 percent adherence to zidovudine prophylaxis or adherence that was not documented, breast-feeding, and maternal initiation of highly active antiretroviral therapy during pregnancy.
Characteristics of the mother, the delivery, and the infant were compared among the treatment groups with the use of the chi-square and Kruskal–Wallis tests. The Kaplan–Meier method and Greenwood's formula were used to estimate transmission rates and their standard errors. The time to the first positive HIV test was considered the time to the end point. Data on infants with negative HIV test results were censored at the time of their last HIV test. The method developed by Balasubramanian and Lagakos, which does not require a predefined operational definition of HIV infection, was used for confirmation; the results are not presented, because they were not different from the transmission rates estimated with the Kaplan–Meier method and Greenwood's formula.16
The differential effect of nevirapine was tested by a comparison within subgroups, defined according to known risk factors for transmission, of the difference in transmission rates between the placebo–placebo group and the nevirapine–nevirapine group (before the first interim analysis) and between the nevirapine–placebo group and the nevirapine–nevirapine group (at the final analysis). In case of rejection of homogeneity of the effect of nevirapine across subgroups with the use of a chi-square test,12 the differential effect was also examined within each subgroup. Except for noninferiority testing, all reported P values are two-sided, without adjustment for multiple testing. Adverse events in mothers and infants were analyzed from enrollment until six months after the birth of the infant.
Results
Enrollment
Of 3061 pregnant women who underwent testing for HIV at the study sites and whose results were positive, 1844 were randomly assigned to study treatment and 1807 were followed through to delivery. Of those not enrolled, 316 women declined enrollment, 395 moved to another town or were lost to follow-up, 50 enrolled in a perinatal nevirapine pharmacokinetics substudy, 104 delivered before pre-enrollment evaluations, 129 terminated their pregnancy, 5 had a spontaneous abortion, 3 started highly active antiretroviral therapy, 2 died before inclusion, and 213 did not meet the inclusion criteria, including 184 who delivered after less than two weeks of zidovudine prophylaxis and were offered open-label nevirapine. Thirty-nine women randomly assigned to the placebo–placebo group were excluded from the analysis because they were provided with open-label nevirapine after the first interim analysis. There were 12 twin pregnancies and 14 fetal deaths (including 1 twin). Enrollment, loss to follow-up, pregnancy outcomes, and available end points for each treatment group in the study are summarized in Figure 1Figure 1
Treatment Assignment, Loss to Follow-up, and Outcome of Pregnancy.. End points were available for 97.6 percent of the 1766 live-born infants included in the analysis.Characteristics of the Women, Deliveries, and Infants
Baseline characteristics of the women, the deliveries, and the newborns were similar across treatment groups (Table 1Table 1
Characteristics of Mothers, Deliveries, and Infants in the Study, According to the Treatment Assignment.). Zidovudine prophylaxis was initiated at a median of 28.7 weeks' gestation. The median duration of zidovudine prophylaxis was 9.7 weeks. The median CD4 count among the women was 372 cells per cubic millimeter, and the median viral load was 4.0 log10 copies per milliliter. Fifty-six women had received antiretroviral therapy during a previous pregnancy.Thirteen percent of the women delivered at or before 37 weeks' gestation. The median interval between the onset of labor and administration of a dose of the assigned treatment was 2.1 hours, and the median interval between receipt of the dose of the assigned treatment and delivery was 6.5 hours. Seventy women received two doses of the assigned treatment because of false or prolonged labor. Twenty percent of the deliveries were by cesarean section, of which 28 percent were performed before the onset of labor.
Nine percent of the infants weighed less than 2500 g (5.5 lb) at birth. The median interval between birth and administration of the first dose of the assigned treatment was 48.4 hours. Eight percent of infants received zidovudine for at least one month, because their mothers had received less than four weeks of zidovudine prophylaxis. There was one report of breast-feeding by the mother.
Analysis of Efficacy
First Interim Analysis
In women who delivered by May 2, 2002, the as-randomized transmission rate among those in the nevirapine–nevirapine group was 1.1 percent (95 percent confidence interval, 0.3 to 2.2), which was significantly lower than the rate of 6.3 percent (95 percent confidence interval, 3.8 to 8.9) in the placebo–placebo group (P<0.001). This finding confirmed the results of the first interim analysis, at which time the data and safety monitoring board recommended stopping the placebo–placebo regimen. In the nevirapine–placebo group, the rate was 2.1 percent (95 percent confidence interval, 0.6 to 3.7). Per-protocol transmission rates were very similar (Table 2Table 2
Kaplan–Meier Estimates of the Rate of Transmission of HIV at Six Months, According to Assigned and Actual Treatment.).Final Analysis
The final per-protocol transmission rate among those in the nevirapine–nevirapine group (1.9 percent; 95 percent confidence interval, 0.9 to 3.0) was not statistically inferior to the rate in the nevirapine–placebo group (2.8 percent; 95 percent confidence interval, 1.5 to 4.1). The upper limit of the one-sided confidence interval of the difference between these observed rates was 2.2, which was below the predefined 2.5 percent inferiority threshold. The rates in the as-randomized analysis were similar — 2.0 percent (95 percent confidence interval, 1.0 to 3.1) in the nevirapine–nevirapine group and 2.8 percent (95 percent confidence interval, 1.6 to 4.1) in the nevirapine–placebo group.
Other Analyses of Transmission
Among infants, the rate of testing positive for HIV within three days after birth in the placebo–placebo group (3.1 percent) was significantly higher than the rate among mothers in the study groups assigned to receive nevirapine before the interim analysis (0.4 percent) (P<0.001) (Table 2). In the final analysis, the overall rate of testing positive within three days after birth was 1.3 percent (95 percent confidence interval, 0.7 to 1.9). An analysis of the rate of death or HIV infection in infants before six months of age did not modify the conclusions of the efficacy analysis (Table 3Table 3
Estimates of the Rate of Transmission of HIV or Death at Six Months, According to Treatment Assignment.).Effect of Nevirapine According to Known Risk Factors for Transmission
Nevirapine had an effect according to the known risk factors for transmission, including viral load and CD4 count at baseline, gestational age at the initiation of zidovudine treatment, gestational duration, and the duration of zidovudine prophylaxis, although the effect often varied across subgroups (Table 4Table 4
Effect of Nevirapine among Infants with Known Risk Factors for Transmission of HIV.).2,5,17-21 In addition, the nevirapine–nevirapine regimen was somewhat superior to the nevirapine–placebo regimen in most subgroups.Maternal Safety
No severe rashes were observed. At 10 days, mild rashes were reported in 3.8 percent of mothers. Alanine aminotransferase levels were 36 to 42 IU per liter in 8.5 percent of mothers and 43 to 69 IU per liter in 0.9 percent (none of the mothers had levels above 70 IU per liter); there was no significant difference among the treatment groups. Rates of serious adverse events were similar across the groups (216 reports) and were related to pregnancy (59 percent), infection or HIV (26 percent), possibly zidovudine prophylaxis (anemia in 7 percent), possibly nevirapine (e.g., allergic reaction during therapy in one woman), and other conditions (7 percent).
Infant Safety
In infants, the rates of rash were 15.9 percent and 7.5 percent at 10 and 45 days of life, respectively, with no significant difference among treatment groups. Likewise, increases in alanine aminotransferase levels (36 to 69 IU per liter in 4.8 percent of infants and 260 IU per liter in one infant; none had levels above 350 IU per liter) and the presence of hyperbilirubinemia were not associated with exposure to nevirapine. The rates of serious adverse events were similar across treatment groups (598 reports) and were related to neonatal or obstetrical conditions (11 percent), to congenital abnormalities (6 percent), to any infection, including HIV (72 percent), possibly to zidovudine (anemia in 2 percent), and to other causes (9 percent). Prolonged neonatal icterus (1 percent) was classified as possibly related to nevirapine even in the placebo–placebo group, since classification was performed by persons blinded to treatment assignment. Nineteen infants died within six months after birth (Table 3).
Discussion
This study demonstrates the high efficacy of adding a single dose of nevirapine in the mother, with or without a dose in the infant, to oral zidovudine prophylaxis for the reduction of perinatal transmission of HIV. The observed reduction by 80 percent that led to the early interruption of enrollment in the placebo–placebo group was much higher than we had hypothesized when we designed the study. The transmission rate observed in the placebo–placebo group was consistent with rates observed in other studies in which zidovudine prophylaxis was initiated at the beginning of the last trimester of pregnancy,1,19-21 in particular in our previous trial, which was performed in a similar population.5
Although the efficacy of a single maternal dose of nevirapine was declared statistically noninferior to that of a maternal dose plus an infant dose with the use of our predetermined criteria (2.5 percent as the upper limit of the one-sided 95 percent confidence interval for the difference between the observed rates of transmission), in fact, two doses appeared consistently better than one throughout our analysis (Table 4). Moreover, because the nevirapine–placebo group had a somewhat lower median viral load at baseline than the nevirapine–nevirapine group, the difference in transmission rates might be an underestimate. On the basis of these findings and for additional logistic reasons, the ministry of public health in Thailand has recommended administration of nevirapine to both mother and infant, with a slight modification, that of giving nevirapine to the mother on arrival at the hospital and to the infant as soon as possible after birth.22
The percentage of infants with a positive HIV test within three days after birth was significantly lower in the nevirapine–nevirapine and the nevirapine–placebo groups than in the placebo–placebo group. This surprising finding suggests either that infants become HIV-positive earlier after infection than previously suspected or that perinatal nevirapine may delay the detection of HIV positivity or even abort infection completely when transmission occurs in the last few weeks of pregnancy.
Newborns in this study were formula-fed. This recommendation, made by the Ministry of Public Health in 1993, is strongly adhered to and has been shown to have no negative effect either on the health of the infant or on the promotion of breast-feeding among HIV-negative women.5,23,24
In the South African Intrapartum Nevirapine Trial, the rate of intrapartum transmission of HIV was three times as high when the mother had received nevirapine less than two hours before delivery as when the mother had received it earlier.25 Our study did not confirm this finding. However, since the administration of nevirapine to infants appears to be safe whatever the delay between birth and receipt of the drug7,25 and given that in clinical practice women may take their nevirapine dose later during labor and stay in the hospital for a shorter period, it may be preferable to administer the dose of nevirapine to the infant shortly after birth, with the first dose of zidovudine.
In the Pediatric AIDS Clinical Trials Group study known as PACTG 316, which evaluated the efficacy of perinatal nevirapine therapy added to standard antiretroviral therapy, no benefit of nevirapine was shown.26 The effect of nevirapine was not observed even in the subgroup of women who received only zidovudine in addition to nevirapine. This subgroup, however, may have been selected to receive zidovudine monotherapy because of the subjects' low viral load. In addition, 43 percent of the women in the group delivered by planned cesarean section. We also found that in the subgroup of women whose viral load at entry was less than 25,000, the transmission rate was very low in the placebo–placebo group (2 percent) and only marginally lower in the nevirapine groups. Although a subgroup analysis has the potential for bias, the effect of perinatal nevirapine was observed in most of the subgroups, a finding that suggests that there is no population for whom nevirapine prophylaxis would not be beneficial.
The discovery of drug-resistance mutations in a substantial proportion of the recipients of perinatal nevirapine27-34 has raised questions of a possible risk to mothers who subsequently receive nonnucleoside reverse-transcriptase inhibitors as therapy for their own disease. The resistance consequences among the participants of our study are described by Jourdain et al. elsewhere in this issue of the Journal.35 The maternal risk is juxtaposed with the clear benefit to the babies. The relative value of this or other interventions in any particular setting will depend on considerations of cost, medical logistics, and drug access, as well as on data from future studies of outcomes in women receiving both perinatal prophylaxis and antiretroviral therapy.36 Nevirapine at delivery added to third-trimester zidovudine results in very low transmission rates with minimal medical and financial burdens — rates that are very similar to those achieved with more complex, expensive, and potentially toxic multidrug maternal regimens.37-43
Supported by grants from the National Institutes of Health (5 R01 HD 39615); the Agence Nationale de Recherches sur le Sida (ANRS 12-08); the Ministry of Public Health, Thailand; the Institut de Recherche pour le Développement, France; the Institut National d'Etudes Démographiques, France; the Department of Technical and Economic Cooperation, Thailand; Boehringer Ingelheim; GlaxoSmithKline (which provided the zidovudine); and Roche Molecular Systems.
Dr. Jourdain reports having equity in Aventis.
We are indebted to S. Hammer and M. Tod for their contribution to the design of the study; to M.P. Kieffer for assistance in preparing the initial trial proposal; to the data and safety monitoring committee members V. Phoolcharoen, D. Costagliola, V. Vithayasai, A. Chaovavanich, for their advice and support throughout the trial; to the staff of the Perinatal HIV Prevention Trial, as follows: for administrative support: N. Chaiboonruang, Y. Thita, P. Pirom, D. Tiptepin, N. Pawadee, R. Klaijak, W. Ruangphornwisut; tracking and supplies: K. Taninard, P. Asongchaiwatanakul, S. Phonin; safety monitoring: S. Chalermpantmetagul, R. Peongjakta; sites monitoring: P. Sukrakanchana, A. Saiphueng, B. Yapuang, W. Pongchaisit, Y. Yensuang, B. Subhamitra, C. Kanabkaew, C. Puttimit, J. Wallapachai, N. Kruenual, N. Kongstan, N. Krapunpongsakul, R. Wongchai, S. Thammajitsagul, S. Jina, N. Seetapun; data management: R. Seubmongkolchai, A. Maleesatharn, J. Suewan, N. Kawee, S. Chailert, S. Tanasri, A. Wongja, K. Yoddee, M. Nuchniyom, K. Chaokasem, P. Supinya, J. Maneechan, K. Suebmongkolchai, S. Tansenee, A. Seubmongkolchai, C. Pholhinkong, C. Chimplee, K. Saopang, N. Karbkam, P. Chusut, P. Onnoy, S. Aumtong; and laboratory: T. Cressey, W. Khamduang, A. Preedam, A. Kummee, K. Janjaroen, M. Sumonwiriya, P. Chanthubthong, W. Boonprasit, J. Kamkorn, P. Tungyai, S. Kanthawong, S. Kunkeaw; to the Thai Ministry of Public Health for advice and assistance: Office of the Permanent Secretary, Department of Health, Department of Communicable Diseases Control, and Provincial Hospitals Division, especially, M. Teeratantikanont, P. Amornwichet, V. Chokevivat, T. Siraprapasiri, T Liewsaree, W. Liewsaree, P. Kantipong, C. Bowonwatanuwong, P. Leenasirimakul, A. Nilmanat, A. Chutanunta, O. Kamsao, W. Panitsuk, P. Pathipvanich; and Chiang Mai University: W. Sirirungsi, P. Lechanachai, U. Haesungcharern, A. Matanasaravoot; to the microbiology reference laboratories: R. Sutthent, P. Auewarakul (Mahidol University, Thailand); A.M. Comeau, J. Gerstel-Thompson (University of Massachusetts), F. Barin (Tours University, France); to the National Institute of Child Health and Human Development: A. Willoughby, B. Nugent, L. Mofenson; to Boehringer Ingelheim: E. Van Steenberge; to GlaxoSmithKline: S. Chinnapha, W. Rungsiyapornrat; to the following colleagues who contributed to this project in many critical ways: M. Essex, P. Matangkhasombut, A. Patterson, P. Casky, P. Jacob, J. Sullivan, C. Bellec, E. Kiley, J. Morcos, M.L. Bezencon, U. Thisyakorn, M. Mirochnich, A. Kuo, D. Bray, K. Young, A. Kuo, N. Briand, R. Balasubramanian; to all members of the hospital teams; and to the women and children who participated in this study.
Source Information
From Epidémiologie Clinique, Santé Maternelle et Infantile et Sida, Institut de Recherche pour le Développement, Paris (M.L., G.J., S.L., N.N.-G.-H.); the Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston (M.L., G.J., N.N.-G.-H.); Institut National d'Etudes Démographiques, Paris (S.L.); INSERM, Erm 0321, Paris (J.Y.M.); the Family Health Research Center, Mahidol University, Bangkok, Thailand (S. Koetsawang); the Ministry of Public Health, Bangkok, Thailand (S. Kanshana, V.T.); and Children's Hospital and the Department of Pediatrics, Harvard Medical School — both in Boston (K.M.).
Address reprint requests to Dr. Lallemant at the Perinatal HIV Prevention Trial — Institut de Recherche pour le Développement, Unité 54, 29/7-8 Samlan Rd., Soi 1 Prasing Muang, Chiang Mai 50200, Thailand, or at marc@phpt.org.
The coinvestigators and study coordinators of the Perinatal HIV Prevention Trial (Thailand) are listed in the Appendix.
Appendix
The following sites and principal investigators participated in the Perinatal HIV Prevention Trial (Thailand) (the number of women enrolled at each hospital is given in parentheses): Rayong (149): S. Ariyadej, W. Karnchanamayul, P. Dumrongkitchaiporn, C. Pinyowittayakool, C. Tantiyawarong; Hat Yai (96): S. Lamlertkittikul, B. Warachit, K. Veerapradist; Samutsakorn (90): T. Sukhumanant, P. Thanasiri, C. Pinsuwan; Samutprakarn (90): P. Sabsanong, C. Sriwacharakarn, M. Hongsawinitkul; Nakhonpathom (84): S. Bunjongpak, V. Chalermpolprapa, P. Hirunchote; Bhumibol Adulyadej (76): K. Kengsakul, S. Prommas, P. Layangool, P. Prateeprat, Y. Vonglertvit; Banglamung (66): K. Boonrod, J. Ithisuknanth, S. Sirithadthamrong, P. Jittiwattanapongs; Chonburi (65): N. Chotivanich, S. Hongsiriwon, P. Kittikoon, C. Tantiyawarong; Somdej Prapinklao (65): S. Suphanich, P. Kanchanakitsakul, B. Tapawal, N. Kamolpakorn, P. Sunalai; Chiangrai Provincial (64): R. Hansudewechakul, J. Achalapong, R. Srismith, S. Yanpaisan; Prapokklao (61): P. Yuthavisuthi, C. Ngampiyasakul, D. Sinthuvanich; Pranangklao (61): S. Pipatnakulchai, S. Watanayothin, S. Hongyok; Health Promotion Region 10 Chiang Mai (60): A. Limtrakul, W. Jitphiankha, S. Sethavanich, V. Sittipiyasakul; Somdej Pranangchao (58): W. Pornkitprasarn, T. Hinjiranandana, W. Rutirawat; Klaeng (52): S. Hotrawarikarn, S. Techapalokul, S. Sungpapan; Buddhachinaraj (52): W. Wannapira, W. Ardong, P. Thanomrat, W. Boonyawatana; Chacheongsao (51): A. Kanjanasing, R. Kwanchaipanich, R. Kaewsonthi, C. Jirawison, V. Latdhivongsakorn; Mae Sai (49): S. Kunkongkapan, T. Meephian, K. Kongsing; Khon Kaen (38): J. Ratanakosol, S. Tanupattarachai, M. Onchan, V. Jarupoonphol; Mae Chan (37): S. Buranabanjasatean, S. Piyaworawong; Kalasin (37): B. Suwannachat, S. Srirojana, S. Nitpanich; Lamphun (35): W. Matanasaravoot, P. Wannarit, K. Pagdi, R. Somsamai, C. Wannalit, S. Yanpaisan; Phaholpolphayuhasena (35): Y. Srivarasat, P. Attavijtrakarn, T. Buddhaboriwan; Health Promotion Region I Bangkok (34): S. Sirinontakan, W. Laphikanont, B. Ngamsiriudom, C. Kommongkol; Ratchaburi (34): T. Chonladarat, N. Pinyotrakool, P. Malitong, O. Bamroongshawkasem, M. Jittwatanakorn, P. Bunjongjit; Chiang Kham (32): C. Putiyanun, P. Jittamala, C. Kulkolakan; Health Promotion Region 6 Khon Kaen (31): N. Winiyakul, S. Hanpinitsak, W. Sinchai; Roi-et (31): W. Atthakorn, P. Ananpatharachai, W. Supanchaimat; Phan (29): S. Jungpichanvanich, T. Changchit, S. Suwan; Nakornping (28): V. Gomuthbutra, S. Kanjanavanit, S. Kahintapongs, C. Sirinirundr, Nong Khai (27): N. P. Ruttana-Aroongorn, S. Potchalongsin, T. Wichatrong; Phayao Provincial (26): S. Bhakeecheep, S. Sangsawang, S. Techakulviroj, S. Attawibool; Srinagarind (26): P. Kosalaraksa, C. Sakondhavat, W. Laupattarakasem, S. Kraitrakul; Nopparat Rajathanee (23): S. Surawongsin, S. Ruangsirinusorn, T. Chanpoo, N. Thamanavat, P. Hotrarapavanond; Mahasarakam (21): S. Nakhapongse, S. Tonmat, K. Kovitanggoon, W. Worngsatthanaphong; Kranuan Crown Prince (16): R. Thongdej, T. Chaiyabut, P. Kovit, S. Benchakhanta, A. Rattanaparinya; Prajaksilapakom Army (15): D. Langkafa, S. Pratchayakul, W. Srichandraphan.
- References
References
1
Connor EM ,Sperling RS ,Gelber R , et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-1180
Full Text | Web of Science | Medline2
Sperling RS ,Shapiro DE ,Coombs RW , et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996;335:1621-1629
Full Text | Web of Science | Medline3
Mofenson LM ,McIntyre JA . Advances and research directions in the prevention of mother-to-child HIV-1 transmission. Lancet 2000;355:2237-2244
CrossRef | Web of Science | Medline4
Kanshana S ,Thewanda D ,Teeraratkul A , et al. Implementing short-course zidovudine to reduce mother-infant HIV transmission in a large pilot program in Thailand. AIDS 2000;14:1617-1623
CrossRef | Web of Science | Medline5
Lallemant M ,Jourdain G ,Le Coeur S , et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. N Engl J Med 2000;343:982-991
Full Text | Web of Science | Medline6
Amornwichet P ,Teeraratkul A ,Simonds RJ , et al. Preventing mother-to-child HIV transmission: the first year of Thailand's national program. JAMA 2002;288:245-248
CrossRef | Web of Science | Medline7
Guay LA ,Musoke P ,Fleming T , et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999;354:795-802
CrossRef | Web of Science | Medline8
Ministry of Public Health. National guidelines for the clinical management of HIV infection in children and adults. Nonthaburi, Thailand: AIDS Division, Department of Communicable Disease Control, 2000.
9
1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Recomm Rep 1999;48:1-59, 61
10
1995 Revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. MMWR Recomm Rep 1995;44:1-11
11
Revised recommendations for HIV screening of pregnant women. MMWR Recomm Rep 2001;50:63-85
Medline12
Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: John Wiley, 1981:161-5.
13
O'Brien PC ,Fleming TR . A multiple testing procedure for clinical trials. Biometrics 1979;35:549-556
CrossRef | Web of Science | Medline14
Lan KKG ,DeMets DL . Changing frequency of interim analysis in sequential monitoring. Biometrics 1989;45:1017-1020
CrossRef | Web of Science | Medline15
Ellenberg JH. Intention-to-treat analysis. In: Redmond CK, Colton T, eds. Biostatistics in clinical trials. Chichester, England: John Wiley, 2001:245-9.
16
Balasubramanian R ,Lagakos SW . Estimation of the timing of perinatal transmission of HIV. Biometrics 2001;57:1048-1058
CrossRef | Web of Science | Medline17
Mofenson LM ,Lambert JS ,Stiehm ER , et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. N Engl J Med 1999;341:385-393
Full Text | Web of Science | Medline18
Shapiro DE ,Sperling RS ,Coombs RW . Effect of zidovudine on perinatal HIV-1 transmission and maternal viral load. Lancet 1999;354:156-156
CrossRef | Web of Science | Medline19
Wade NA ,Birkhead GS ,Warren BL , et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998;339:1409-1414
Full Text | Web of Science | Medline20
Matheson PB ,Abrams EJ ,Thomas PA , et al. Efficacy of antenatal zidovudine in reducing perinatal transmission of human immunodeficiency virus type 1. J Infect Dis 1995;172:353-358
CrossRef | Web of Science | Medline21
Simpson BJ ,Shapiro ED ,Andiman WA . Reduction in the risk of vertical transmission of HIV-1 associated with treatment of pregnant women with orally administered zidovudine alone. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:145-152
CrossRef | Medline22
Guidelines for the management of prevention of mother to child transmission of HIV in Thailand: policy of prevention of mother to child transmission of HIV in Thailand. Nonthaburi, Thailand: Ministry of Public Health, Department of Health, December 2003.
23
Kanshana S ,Simonds RJ . National program for preventing mother-child HIV transmission in Thailand: successful implementation and lessons learned. AIDS 2002;16:953-959
CrossRef | Web of Science | Medline24
Talawat S ,Dore GJ ,Le Coeur S ,Lallemant M . Infant feeding practices and attitudes among women with HIV infection in northern Thailand. AIDS Care 2002;14:625-631
CrossRef | Web of Science | Medline25
Moodley D ,Moodley J ,Coovadia H , et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 2003;187:725-735
CrossRef | Web of Science | Medline26
Dorenbaum A ,Cunningham CK ,Gelber RD , et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA 2002;288:189-198
CrossRef | Web of Science | Medline27
Jackson JB ,Becker-Pergola G ,Guay LA , et al. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS 2000;14:F111-F115
CrossRef | Web of Science | Medline28
Eshleman SH ,Mracna M ,Guay LA , et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001;15:1951-1957
CrossRef | Web of Science | Medline29
Cunningham CK ,Chaix ML ,Rekacewicz C , et al. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of Pediatric AIDS Clinical Trials Group protocol 316. J Infect Dis 2002;186:181-188
CrossRef | Web of Science | Medline30
Morris L ,Pillay C ,Chezzi C , et al. Low frequency of the V106M mutation among HIV-1 subtype C-infected pregnant women exposed to nevirapine. AIDS 2003;17:1698-1700
CrossRef | Web of Science | Medline31
Kantor R ,Lee E ,Johnston E , et al. Rapid flux in non-nucleoside reverse transcriptase inhibitor resistance mutations among subtype C HIV-1-infected women after single dose nevirapine. Antiviral Ther 2003;8:S85-S85 abstract.32
Chaix ML, Montcho C, Ekouevi DK, et al. Genotypic resistance analysis in women who received intrapartum nevirapine associated to a short course of zidovudine to prevent perinatal HIV-1 transmission: the Ditrame Plus ANRS 1201/02 Study, Abidjan, Côte d'Ivoire. In: Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 8–11, 2004:657. abstract.
33
Chalermchokcharoenkit A, Asavapiriyanont S, Teeraratkul A, et al. Combination short-course zidovudine plus 2-dose nevirapine for prevention of mother-to-child transmission: safety, tolerance, transmission, and resistance results. In: Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 8–11, 2004:96. abstract.
34
Martinson N, Morris L, Gray G, et al. HIV resistance and transmission following single-dose nevirapine in a PMTCT cohort. In: Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 8–11, 2004:38. abstract.
35
Jourdain G ,Ngo-Giang-Huong N ,Le Coeur S , et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004;351:229-240
Full Text | Web of Science | Medline36
World Health Organization. Antiretroviral drugs and the prevention of mother-to-child transmission of HIV infection in resource-limited settings: expert consultation, Geneva, 5-6 February 2004: a summary of main points from the meeting. (Accessed June 18, 2004, at http://www.who.int/3by5/arv_pmtct/en/.)
37
Bucceri AM ,Somigliana E ,Matrone R , et al. Combination antiretroviral therapy in 100 HIV-1-infected pregnant women. Hum Reprod 2002;17:436-441
CrossRef | Web of Science | Medline38
Cooper ER ,Charurat M ,Mofenson L , et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002;29:484-494
CrossRef | Web of Science | Medline39
Tuomala RE ,Shapiro DE ,Mofenson LM , et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 2002;346:1863-1870
Full Text | Web of Science | Medline40
Wimalasundera RC ,Larbalestier N ,Smith JH , et al. Pre-eclampsia, antiretroviral therapy, and immune reconstitution. Lancet 2002;360:1152-1154
CrossRef | Web of Science | Medline41
Shapiro D, Tuomala R, Pollack H, et al. Mother-to-child HIV transmission risk according to antiretroviral therapy, mode of delivery, and viral load in 2895 U.S. women (PACTG 367). In: Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 8–11, 2004:99. abstract.
42
Shepard KV. Important new safety information: clarification of risk factors for severe, life-threatening and fatal hepatotoxicity with VIRAMUNE (nevirapine). Ridgefield, Conn.: Boehringer Ingelheim Pharmaceuticals, February 2004.
43
Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, D.C.: Department of Health and Human Services, March 23, 2004.
- Citing Articles (137)
Citing Articles
1
R. B. Van Dyke, N. Ngo-Giang-Huong, D. E. Shapiro, L. Frenkel, P. Britto, A. Roongpisuthipong, I. A. Beck, P. Yuthavisuthi, S. Prommas, T. Puthanakit, J. Achalapong, N. Chotivanich, W. Rasri, T. R. Cressey, R. Maupin, M. Mirochnick, G. Jourdain, . (2011) A Comparison of 3 Regimens to Prevent Nevirapine Resistance Mutations in HIV-Infected Pregnant Women Receiving a Single Intrapartum Dose of Nevirapine. Clinical Infectious Diseases
CrossRef2
M. Cavarelli, G. Scarlatti. (2011) Human immunodeficiency virus type 1 mother-to-child transmission and prevention: successes and controversies. Journal of Internal Medicineno-no
CrossRef3
Nandi Siegfried, Lize van der Merwe, Peter Brocklehurst, Tin Tin Sint, Nandi Siegfried. 2011. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. .
CrossRef4
Paul Thistle, Shelly Bolotin, Eugene Lam, Dan Schwarz, Richard Pilon, Billy Ndawana, Andrew E. Simor, Michael Silverman. (2011) Highly active anti-retroviral therapy in the prevention of mother-to-child transmission of HIV in rural Zimbabwe during the socio-economic crisis. Medicine, Conflict and Survival 27:3, 165-176
CrossRef5
Scott Dryden-Peterson, Roger L Shapiro, Michael D Hughes, Kathleen Powis, Anthony Ogwu, Claire Moffat, Sikhulile Moyo, Joseph Makhema, Max Essex, Shahin Lockman. (2011) Increased Risk of Severe Infant Anemia After Exposure to Maternal HAART, Botswana. JAIDS Journal of Acquired Immune Deficiency Syndromes 56:5, 428-436
CrossRef6
Yung-Chih Kuo, Jui-Fang Chung. (2011) Physicochemical properties of nevirapine-loaded solid lipid nanoparticles and nanostructured lipid carriers. Colloids and Surfaces B: Biointerfaces 83:2, 299-306
CrossRef7
BJ Dorton, J Mulindwa, MS Li, NT Chintu, CJ Chibwesha, F Mbewe, LM Frenkel, JSA Stringer, BH Chi. (2011) CD4+ cell count and risk for antiretroviral drug resistance among women using peripartum nevirapine for perinatal HIV prevention. BJOG: An International Journal of Obstetrics & Gynaecology 118:4, 495-499
CrossRef8
Chokechai Rongkavilit, Basim I. Asmar. (2011) Advances in Prevention of Mother-to-Child HIV Transmission: The International Perspectives. The Indian Journal of Pediatrics 78:2, 192-204
CrossRef9
Vijaya Karthekeyani, Glory Alexander, Eileen Solomon, Sarita Rao, P. S. S. Sunder Rao. (2011) Prevention of mother to child transmission of HIV: Our experience in South India. The Journal of Obstetrics and Gynecology of India 61:1, 62-66
CrossRef10
Amin S. Hassan, Erick M. Sakwa, Helen M. Nabwera, Miriam M. Taegtmeyer, Robert M. Kimutai, Eduard J. Sanders, Ken K. Awuondo, Maureen N. Mutinda, Catherine S. Molyneux, James A. Berkley. (2011) Dynamics and Constraints of Early Infant Diagnosis of HIV Infection in Rural Kenya. AIDS and Behavior
CrossRef11
Ziad El-Khatib, Anna Ekstrom, Ashraf Coovadia, Elaine J Abrams, Max Petzold, David Katzenstein, Lynn Morris, Louise Kuhn. (2011) Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa - a prospective cohort study. BMC Public Health 11:1, 88
CrossRef12
Avinash K. Shetty, Yvonne A. Maldonado. 2011. Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome in the Infant. , 622-660.
CrossRef13
Alexandra M. M. Antunes, David A. Novais, J. L. Ferreira da Silva, Pedro P. Santos, M. Conceição Oliveira, Frederick A. Beland, M. Matilde Marques. (2011) Synthesis and oxidation of 2-hydroxynevirapine, a metabolite of the HIV reverse transcriptase inhibitor nevirapine. Organic & Biomolecular Chemistry 9:22, 7822
CrossRef14
Jonathan S Karpelowsky, Alastair JW Millar, Nelleke van der Graaf, Guido van Bogerijen, Heather J Zar. (2011) Outcome of HIV-exposed uninfected children undergoing surgery. BMC Pediatrics 11:1, 69
CrossRef15
SO Mepham, RM Bland, M-L Newell. (2011) Prevention of mother-to-child transmission of HIV in resource-rich and -poor settings. BJOG: An International Journal of Obstetrics & Gynaecology 118:2, 202-218
CrossRef16
The Kesho Bora Study Group. (2011) Safety and effectiveness of antiretroviral drugs during pregnancy, delivery and breastfeeding for prevention of mother-to-child transmission of HIV-1: The Kesho Bora Multicentre Collaborative Study rationale, design, and implementation challenges. Contemporary Clinical Trials 32:1, 74-85
CrossRef17
Athena P. Kourtis, Marc Bulterys. (2010) Mother-to-Child Transmission of HIV: Pathogenesis, Mechanisms and Pathways. Clinics in Perinatology 37:4, 721-737
CrossRef18
Paul J. Weidle, Steven Nesheim. (2010) HIV Drug Resistance and Mother-to-Child Transmission of HIV. Clinics in Perinatology 37:4, 825-842
CrossRef19
Philip L. Bulterys, Sudeb C. Dalai, David A. Katzenstein. (2010) Viral Sequence Analysis from HIV-Infected Mothers and Infants: Molecular Evolution, Diversity, and Risk Factors for Mother-To-Child Transmission. Clinics in Perinatology 37:4, 739-750
CrossRef20
Mamatha M. Lala, Rashid H. Merchant. (2010) Vertical Transmission of HIV–An Update. The Indian Journal of Pediatrics 77:11, 1270-1276
CrossRef21
Iain J. MacLeod, Christopher F. Rowley, Ibou Thior, Carolyn Wester, Joseph Makhema, Max Essex, Shahin Lockman. (2010) Minor resistant variants in nevirapine-exposed infants may predict virologic failure on nevirapine-containing ART. Journal of Clinical Virology 48:3, 162-167
CrossRef22
Seni Kouanda, Halima Tougri, Mireille Cissé, Jacques Simporé, Virginio Pietra, Boukaré Doulougou, Gautier Ouédraogo, Charlemagne Marie Ouédraogo, Robert Soudré, Blaise Sondo. (2010) Impact of maternal HAART on the prevention of mother-to-child transmission of HIV: results of an 18-month follow-up study in Ouagadougou, Burkina Faso. AIDS Care 22:7, 843-850
CrossRef23
Chasela, Charles S., Hudgens, Michael G., Jamieson, Denise J., Kayira, Dumbani, Hosseinipour, Mina C., Kourtis, Athena P., Martinson, Francis, Tegha, Gerald, Knight, Rodney J., Ahmed, Yusuf I., Kamwendo, Deborah D., Hoffman, Irving F., Ellington, Sascha R., Kacheche, Zebrone, Soko, Alice, Wiener, Jeffrey B., Fiscus, Susan A., Kazembe, Peter, Mofolo, Innocent A., Chigwenembe, Maggie, Sichali, Dorothy S., van der Horst, Charles M., . (2010) Maternal or Infant Antiretroviral Drugs to Reduce HIV-1 Transmission. New England Journal of Medicine 362:24, 2271-2281
Full Text24
Christopher F. Rowley, Christian L. Boutwell, Esther J. Lee, Iain J. MacLeod, Heather J. Ribaudo, M. Essex, Shahin Lockman. (2010) Ultrasensitive Detection of Minor Drug-Resistant Variants for HIV After Nevirapine Exposure Using Allele-Specific PCR: Clinical Significance. AIDS Research and Human Retroviruses 26:3, 293-300
CrossRef25
Ludimila Paula Vaz Cardoso, Gisner Alves Souza Pereira, Ângela Alves Viegas, Luiza Emylce Pelá Rosado Schmaltz, Mariane Martins de Araújo Stefani. (2010) HIV-1 primary and secondary antiretroviral drug resistance and genetic diversity among pregnant women from central Brazil. Journal of Medical Virology 82:3, 351-357
CrossRef26
Zengquan Zhou, Kathrine Meyers, Xia Li, Qingling Chen, Haoyu Qian, Yunfei Lao, Elvin Geng, Yishan Fan, Shaomin Yang, Michael Chiu, David D Ho. (2010) Prevention of Mother-to-Child Transmission of HIV-1 Using Highly Active Antiretroviral Therapy in Rural Yunnan, China. JAIDS Journal of Acquired Immune Deficiency Syndromes 53, S15-S22
CrossRef27
Tim R Cressey, Marc Lallemant. (2010) Pharmacogenomics and the prevention of mother-to-child transmission of HIV. Pharmacogenomics 11:1, 1-4
CrossRef28
Robert W. Buckheit, Karen M. Watson, Kathleen M. Morrow, Anthony S. Ham. (2010) Development of topical microbicides to prevent the sexual transmission of HIV. Antiviral Research 85:1, 142-158
CrossRef29
Camille Lallemant, Gaston Halembokaka, Gaelle Baty, Nicole Ngo-Giang-Huong, Francis Barin, Sophie Le Coeur. (2010) Impact of HIV/Aids on Child Mortality before the Highly Active Antiretroviral Therapy Era: A Study in Pointe-Noire, Republic of Congo. Journal of Tropical Medicine 2010, 1-6
CrossRef30
S. Chantarangsu, T. R. Cressey, S. Mahasirimongkol, E. Capparelli, Y. Tawon, N. Ngo-Giang-Huong, G. Jourdain, M. Lallemant, W. Chantratita. (2009) Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women. Journal of Antimicrobial Chemotherapy 64:6, 1265-1273
CrossRef31
F. Martin, G. P. Taylor. (2009) The safety of highly active antiretroviral therapy for the HIV-positive pregnant mother and her baby: is 'the more the merrier'?. Journal of Antimicrobial Chemotherapy 64:5, 895-900
CrossRef32
Rebeca Lahoz, Antoni Noguera, Núria Rovira, Albert Català, Emília Sánchez, Rafael Jiménez, Clàudia Fortuny. (2009) Antiretroviral-Related Hematologic Short-term Toxicity in Healthy Infants. The Pediatric Infectious Disease Journal1
CrossRef33
CN Mnyani, JA McIntyre. (2009) Preventing mother-to-child transmission of HIV. BJOG: An International Journal of Obstetrics & Gynaecology 116, 71-76
CrossRef34
(2009) Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1. AIDS 27:7, 825-833
CrossRef35
Neil A Martinson, Lynn Morris, Jeffrey Johnson, Glenda E Gray, Visva Pillay, Johanna Ledwaba, Puleng Dhlamini, Sarah Cohen, Adrian Puren, Jan Steyn, Walid Heneine, James A McIntyre. (2009) Women exposed to single-dose nevirapine in successive pregnancies: effectiveness and nonnucleoside reverse transcriptase inhibitor resistance. AIDS 27:7, 809-816
CrossRef36
Hendramoorthy Maheswaran, Ruth M Bland. (2009) Preventing mother-to-child transmission of HIV in resource-limited settings. Future Virology 4:2, 165-175
CrossRef37
Ashraf Coovadia, Gillian Hunt, Elaine J. Abrams, Gayle Sherman, Tammy Meyers, Gill Barry, Eloise Malan, Belinda Marais, Renate Stehlau, Johanna Ledwaba, Scott M. Hammer, Lynn Morris, Louise Kuhn. (2009) Persistent Minority K103N Mutations among Women Exposed to Single‐Dose Nevirapine and Virologic Response to Nonnucleoside Reverse‐Transcriptase Inhibitor–Based Therapy. Clinical Infectious Diseases 48:4, 462-472
CrossRef38
Elijah Paintsil, Warren A Andiman. (2009) Update on successes and challenges regarding mother-to-child transmission of HIV. Current Opinion in Pediatrics 21:1, 94-101
CrossRef39
A. Spensley, T. Sripipatana, A. N. Turner, C. Hoblitzelle, J. Robinson, C. Wilfert, . (2009) Preventing Mother-to-Child Transmission of HIV in Resource-Limited Settings: The Elizabeth Glaser Pediatric AIDS Foundation Experience. American Journal of Public Health 99:4, 631-637
CrossRef40
June M. McKoy, Charles L. Bennett, Marc H. Scheetz, Virginia Differding, Kevin L. Chandler, Kimberly K. Scarsi, Paul R. Yarnold, Sarah Sutton, Frank Palella, Stuart Johnson, Eniola Obadina, Dennis W. Raisch, Jorge P. Parada. (2009) Hepatotoxicity Associated with Long- versus Short-Course HIV-Prophylactic Nevirapine Use. Drug Safety 32:2, 147-158
CrossRef41
F. Gold, M.-H. Blond, C. Lionnet, I. De Montgolfier. 2009. Particularités de L'exercice Pédiatrique en Maternité dans les Pays en Voie de Développement. , 391-408.
CrossRef42
Nicole Ngo-Giang-Huong, Woottichai Khamduang, Baptiste Leurent, Intira Collins, Issaren Nantasen, Pranee Leechanachai, Wasna Sirirungsi, Aram Limtrakul, Tasana Leusaree, Anne Marie Comeau, Marc Lallemant, Gonzague Jourdain. (2008) Early HIV-1 Diagnosis Using In-House Real-Time PCR Amplification on Dried Blood Spots for Infants in Remote and Resource-Limited Settings. JAIDS Journal of Acquired Immune Deficiency Syndromes 49:5, 465-471
CrossRef43
Guangwu Wang, Nazanin Izadpanah, Christina M.R. Kitchen, Helene B. Bernstein. (2008) Fetal Allostimulation of Maternal Cells: A Potential Mechanism for Perinatal HIV Transmission following Obstetrical Hemorrhage. AIDS Research and Human Retroviruses 24:12, 1545-1554
CrossRef44
Vivian Black, Risa M Hoffman, Catherine A Sugar, Priya Menon, Francois Venter, Judith S Currier, Helen Rees. (2008) Safety and Efficacy of Initiating Highly Active Antiretroviral Therapy in an Integrated Antenatal and HIV Clinic in Johannesburg, South Africa. JAIDS Journal of Acquired Immune Deficiency Syndromes 49:3, 276-281
CrossRef45
Andrea L Ciaranello, George R Seage, Kenneth A Freedberg, Milton C Weinstein, Shahin Lockman, Rochelle P Walensky. (2008) Antiretroviral drugs for preventing mother-to-child transmission of HIV in sub-Saharan Africa: balancing efficacy and infant toxicity. AIDS 22:17, 2359-2369
CrossRef46
Nittaya Phanuphak, Praphan Phanuphak. (2008) Proposed guidelines for the prevention of mother-to-child transmission of HIV in middle-income countries: the Thai Red Cross PMTCT guidelines. Future HIV Therapy 2:6, 551-565
CrossRef47
Tanawan Samleerat, Martine Braibant, Gonzague Jourdain, Alain Moreau, Nicole Ngo‐Giang‐Huong, Pranee Leechanachai, Jittapol Hemvuttiphan, Temsiri Hinjiranandana, Tikamporn Changchit, Boonyarat Warachit, Veera Suraseranivong, Marc Lallemant, Francis Barin. (2008) Characteristics of HIV Type 1 (HIV‐1) Glycoprotein 120 env Sequences in Mother‐Infant Pairs Infected with HIV‐1 Subtype CRF01_AE. The Journal of Infectious Diseases 198:6, 868-876
CrossRef48
Katherine A. Belden, Kathleen E. Squires. (2008) HIV infection in women: Do sex and gender matter?. Current Infectious Disease Reports 10:5, 423-431
CrossRef49
Carine Jasseron, Laurent Mandelbrot, Roland Tubiana, Jean-Paul Teglas, Albert Faye, Catherine Dollfus, Jerome Le Chenadec, Christine Rouzioux, Stephane Blanche, Josiane Warszawski. (2008) Prevention of mother-to-child HIV transmission: similar access for sub-Sahara African immigrants and for French women?. AIDS 22:12, 1503-1511
CrossRef50
Renaud Becquet, Lynne M Mofenson. (2008) Early antiretroviral therapy of HIV-infected infants in resource-limited countries: possible, feasible, effective and challenging. AIDS 22:11, 1365-1368
CrossRef51
Charles Kilewo, Katarina Karlsson, Augustine Massawe, Eligius Lyamuya, Andrew Swai, Fred Mhalu, Gunnel Biberfeld. (2008) Prevention of Mother-to-Child Transmission of HIV-1 Through Breast-Feeding by Treating Infants Prophylactically With Lamivudine in Dar es Salaam, Tanzania. JAIDS Journal of Acquired Immune Deficiency Syndromes 48:3, 315-323
CrossRef52
David E. Shapiro. 2008. Mother to Child Human Immunodeficiency Virus Transmission Trials. .
CrossRef53
G.U. van Zyl, M. Claassen, S. Engelbrecht, J.D. Laten, M.F. Cotton, G.B. Theron, W. Preiser. (2008) Zidovudine with nevirapine for the prevention of HIV mother-to-child transmission reduces nevirapine resistance in mothers from the Western Cape, South Africa. Journal of Medical Virology 80:6, 942-946
CrossRef54
Liesbeth JM Bollen, Sara J Whitehead, Philip A Mock, Wanna Leelawiwat, Suvanna Asavapiriyanont, Amphan Chalermchockchareonkit, Nirun Vanprapar, Tawee Chotpitayasunondh, Janet M McNicholl, Jordan W Tappero, Nathan Shaffer, Rutt Chuachoowong. (2008) Maternal herpes simplex virus type 2 coinfection increases the risk of perinatal HIV transmission: possibility to further decrease transmission?. AIDS 22:10, 1169-1176
CrossRef55
Luis E. Soto-Ramirez, Roberto Rodriguez-Diaz, Adriana S. Durán, Marcelo H. Losso, Horacio Salomón, Manuel Gómez-Carrillo, Sandra Pampuro, D. Robert Harris, Geraldo Duarte, Ricardo S. De Souza, Jennifer S. Read. (2008) Antiretroviral Resistance among HIV Type 1-Infected Women First Exposed to Antiretrovirals during Pregnancy: Plasma versus PBMCs. AIDS Research and Human Retroviruses 24:6, 797-804
CrossRef56
M. Kirere Mathe, D. Sondag-Thull, P. Lepage. (2008) Feasibility of prevention of perinatal HIV infection by nevirapine in rural areas of the northeast Democratic Republic of Congo, 2002–2004. Journal of Medical Virology 80:5, 772-776
CrossRef57
Sabada Dube, Marie-Claude Boily, Owen Mugurungi, Agnes Mahomva, Frank Chikhata, Simon Gregson. (2008) Estimating Vertically Acquired HIV Infections and the Impact of the Prevention of Mother-to-Child Transmission Program in Zimbabwe. JAIDS Journal of Acquired Immune Deficiency Syndromes 48:1, 72-81
CrossRef58
Sunil Saharan, Rakesh Lodha, Ramesh Agarwal, Ashok K. Deorari, Vinod K. Paul. (2008) Perinatal HIV. The Indian Journal of Pediatrics 75:4, 359-362
CrossRef59
Joanna Orne-Gliemann, Renaud Becquet, Didier K Ekouevi, Valériane Leroy, Freddy Perez, François Dabis. (2008) Children and HIV/AIDS: from research to policy and action in resource-limited settings. AIDS 22:7, 797-805
CrossRef60
Steven FJ Callens, Mehri S McKellar, Robert Colebunders. (2008) HIV care and treatment for children in resource-limited settings. Expert Review of Anti-infective Therapy 6:2, 181-190
CrossRef61
James McIntyre, Marc Lallemant. (2008) The prevention of mother-to-child transmission of HIV: are we translating scientific success into programmatic failure?. Current Opinion in HIV and AIDS 3:2, 139-145
CrossRef62
P. A. Coffie, D. K. Ekouevi, M.-L. Chaix, B. Tonwe-Gold, A.-B. Clarisse, R. Becquet, I. Viho, T. N' dri-Yoman, V. r. Leroy, E. J. Abrams, C. Rouzioux, F. o. Dabis. (2008) Maternal 12-Month Response to Antiretroviral Therapy following Prevention of Mother-to-Child Transmission of HIV Type 1, Ivory Coast, 2003- 2006. Clinical Infectious Diseases 46:4, 611-621
CrossRef63
Lynne M. Mofenson. 2008. Prevention of Mother-to-Child Transmission of HIV-1. , 497-512.
CrossRef64
Josiane Warszawski, Roland Tubiana, Jerome Le Chenadec, Stephane Blanche, Jean-Paul Teglas, Catherine Dollfus, Albert Faye, Marianne Burgard, Christine Rouzioux, Laurent Mandelbrot. (2008) Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS 22:2, 289-299
CrossRef65
Concepta Merry, Charles W. Flexner. 2008. Pharmacology of Antiretroviral Drugs. , 171-179.
CrossRef66
Tracy Creek, Amilcar Tanuri, Monica Smith, Khumo Seipone, Molly Smit, Keitumetse Legwaila, Catherine Motswere, Maruping Maruping, Tapologo Nkoane, Ralph Ntumy, Ebi Bile, Madisa Mine, Lydia Lu, Goitebetswe Tebele, Loeto Mazhani, Margarett K. Davis, Thierry H. Roels, Peter H. Kilmarx, Nathan Shaffer. (2008) Early Diagnosis of Human Immunodeficiency Virus in Infants Using Polymerase Chain Reaction on Dried Blood Spots in Botswanaʼs National Program for Prevention of Mother-to-Child Transmission. The Pediatric Infectious Disease Journal 27:1, 22-26
CrossRef67
Lisa R. Hirschhorn, Bisola Ojikutu, William Rodriguez. (2007) Research for Change: Using Implementation Research to Strengthen HIV Care and Treatment Scale‐Up in Resource‐Limited Settings. The Journal of Infectious Diseases 196:s3, S516-S522
CrossRef68
Gonzague Jourdain, Jean‐Yves Mary, Sophie Le Coeur, Nicole Ngo‐Giang‐Huong, Praparb Yuthavisuthi, Aram Limtrakul, Patrinee Traisathit, Kenneth McIntosh, Marc Lallemant, . (2007) Risk Factors for In Utero or Intrapartum Mother‐to‐Child Transmission of Human Immunodeficiency Virus Type 1 in Thailand. The Journal of Infectious Diseases 196:11, 1629-1636
CrossRef69
Tammy Meyers, Harry Moultrie, Kimesh Naidoo, Mark Cotton, Brian Eley, Gayle Sherman. (2007) Challenges to Pediatric HIV Care and Treatment in South Africa. The Journal of Infectious Diseases 196:s3, S474-S481
CrossRef70
Benjamin H Chi, Moses Sinkala, Felistas Mbewe, Ronald A Cantrell, Gina Kruse, Namwinga Chintu, Grace M Aldrovandi, Elizabeth M Stringer, Chipepo Kankasa, Jeffrey T Safrit, Jeffrey SA Stringer. (2007) Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. The Lancet 370:9600, 1698-1705
CrossRef71
James McIntyre, Neil Martinson. (2007) Prophylactic regimens to prevent mother-to-child transmission of HIV and their effect on future therapy. Therapy 4:6, 797-805
CrossRef72
Dara A. Lehman, Carey Farquhar. (2007) Biological mechanisms of vertical human immunodeficiency virus (HIV-1) transmission. Reviews in Medical Virology 17:6, 381-403
CrossRef73
Michelle S McConnell, Paul Bakaki, Chineta Eure, Michael Mubiru, Danstan Bagenda, Robert Downing, Flavia Matovu, Michael C Thigpen, Alan E Greenberg, Mary Glenn Fowler. (2007) Effectiveness of Repeat Single-Dose Nevirapine for Prevention of Mother-to-Child Transmission of HIV-1 in Repeat Pregnancies in Uganda. JAIDS Journal of Acquired Immune Deficiency Syndromes 46:3, 291-296
CrossRef74
Katherine Luzuriaga. (2007) Mother-to-child transmission of HIV: A global perspective. Current Infectious Disease Reports 9:6, 511-517
CrossRef75
Michael K. Hendricks, Brian Eley, Lesley T. Bourne. (2007) Nutrition and HIV/AIDS in infants and children in South Africa: implications for food-based dietary guidelines. Maternal & Child Nutrition 3:4, 322-333
CrossRef76
Soranun Chantarangsu, Tim Cressey, Surakameth Mahasirimongkol, Yardpiroon Tawon, Nicole Ngo-Giang-Huong, Gonzague Jourdain, Marc Lallemant, Wasun Chantratita. (2007) Comparison of the TaqMan and LightCycler systems in evaluation of CYP2B6 516G>T polymorphism. Molecular and Cellular Probes 21:5-6, 408-411
CrossRef77
Michelle S. McConnell, Jeffrey S.A. Stringer, Athena P. Kourtis, Paul J. Weidle, Susan H. Eshleman. (2007) Use of single-dose nevirapine for the prevention of mother-to-child transmission of HIV-1: does development of resistance matter?. American Journal of Obstetrics and Gynecology 197:3, S56-S63
CrossRef78
Elaine J. Abrams, Landon Myer, Allan Rosenfield, Wafaa M. El-Sadr. (2007) Prevention of mother-to-child transmission services as a gateway to family-based human immunodeficiency virus care and treatment in resource-limited settings: rationale and international experiences. American Journal of Obstetrics and Gynecology 197:3, S101-S106
CrossRef79
Mary Glenn Fowler, Margaret A. Lampe, Denise J. Jamieson, Athena P. Kourtis, Martha F. Rogers. (2007) Reducing the risk of mother-to-child human immunodeficiency virus transmission: past successes, current progress and challenges, and future directions. American Journal of Obstetrics and Gynecology 197:3, S3-S9
CrossRef80
Norma S. Harris, Mary Glenn Fowler, Stephanie L. Sansom, Nan Ruffo, Margaret A. Lampe. (2007) Use of enhanced perinatal human immunodeficiency virus surveillance methods to assess antiretroviral use and perinatal human immunodeficiency virus transmission in the United States, 1999-2001. American Journal of Obstetrics and Gynecology 197:3, S33-S41
CrossRef81
A. Faye, S. Pornprasert, J.-Y. Mary, G. Dolcini, M. Derrien, F. Barré-Sinoussi, G. Chaouat, E. Menu, . (2007) Characterization of the main placental cytokine profiles from HIV-1-infected pregnant women treated with anti-retroviral drugs in France. Clinical & Experimental Immunology 149:3, 430-439
CrossRef82
Halima Dao, Lynne M. Mofenson, Rene Ekpini, Charles F. Gilks, Matthew Barnhart, Omotayo Bolu, Nathan Shaffer. (2007) International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update. American Journal of Obstetrics and Gynecology 197:3, S42-S55
CrossRef83
Ouzama Nicholson, David E. Michalik, Sameer Patel, Philip LaRussa, Natalie Neu. (2007) ACUTE HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN A BREAST-FED INFANT IN NEW YORK CITY. The Pediatric Infectious Disease Journal 26:7, 653-655
CrossRef84
Leonardo Palombi, Maria Cristina Marazzi, Albertus Voetberg, N Abdul Magid. (2007) Treatment acceleration program and the experience of the DREAM program in prevention of mother-to-child transmission of HIV. AIDS 21:Suppl 4, S65-S71
CrossRef85
Claire Thorne, Marie-Louise Newell. (2007) HIV. Seminars in Fetal and Neonatal Medicine 12:3, 174-181
CrossRef86
N. Suksomboon, N. Poolsup, S. Ket-aim. (2007) Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection. Journal of Clinical Pharmacy and Therapeutics 32:3, 293-311
CrossRef87
Chifumbe Chintu. (2007) Tuberculosis and human immunodeficiency virus co-infection in children: management challenges. Paediatric Respiratory Reviews 8:2, 142-147
CrossRef88
Neil A Martinson, Didier K Ekouevi, Francois Dabis, Lynn Morris, Pumla Lupodwana, Besigin Tonwe-Gold, Puleng Dhlamini, Renaud Becquet, Jan G Steyn, Val??riane Leroy, Ida Viho, Glenda E Gray, James A McIntyre. (2007) Transmission Rates in Consecutive Pregnancies Exposed to Single-Dose Nevirapine in Soweto, South Africa and Abidjan, C??te d??Ivoire. JAIDS Journal of Acquired Immune Deficiency Syndromes 45:2, 206-209
CrossRef89
Elise Arrivé, François Dabis. (2007) Development of resistance after administration of single-dose nevirapine to prevent mother-to-child transmission of HIV. Future HIV Therapy 1:1, 91-101
CrossRef90
Marc Lallemant, Gonzague Jourdain. (2007) Nevirapine prophylaxis for the prevention of perinatal HIV and the impact of resistance mutations on subsequent therapy. Future HIV Therapy 1:1, 23-27
CrossRef91
P. Rupali, R. Condon, S. Roberts, L. Wilkinson, L. Voss, M. G. Thomas. (2007) Prevention of mother to child transmission of HIV infection in Pacific countries. Internal Medicine Journal 37:4, 216-223
CrossRef92
Elijah Paintsil, Warren A. Andiman. (2007) Care and Management of the Infant of the HIV-1-Infected Mother. Seminars in Perinatology 31:2, 112-123
CrossRef93
Dimitris Rigopoulos, Stamatis Gregoriou, Vasilis Paparizos, Andreas Katsambas. (2007) AIDS in Pregnancy, Part II: Treatment in the Era of Highly Active Antiretroviral Therapy and Management of Obstetric, Anesthetic, and Pediatric Issues. SKINmed 6:2, 79-84
CrossRef94
Hoosen M Coovadia, Nigel C Rollins, Ruth M Bland, Kirsty Little, Anna Coutsoudis, Michael L Bennish, Marie-Louise Newell. (2007) Mother-to-child transmission of HIV-1 infection during exclusive breastfeeding in the first 6 months of life: an intervention cohort study. The Lancet 369:9567, 1107-1116
CrossRef95
Bluma G Brenner. (2007) Resistance and viral subtypes: how important are the differences and why do they occur?. Current Opinion in HIV and AIDS 2:2, 94-102
CrossRef96
Neil A Martinson, Lynn Morris, Glenda Gray, Daya Moodley, Visva Pillay, Sarah Cohen, Puleng Dhlamini, Adrian Puren, Schene Bhayroo, Jan Steyn, James A McIntyre. (2007) Selection and Persistence of Viral Resistance in HIV-Infected Children After Exposure to Single-Dose Nevirapine. JAIDS Journal of Acquired Immune Deficiency Syndromes 44:2, 148-153
CrossRef97
Jimmy Volmink, Nandi Siegfried, Lize van der Merwe, Peter Brocklehurst, Jimmy Volmink. 2007. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. .
CrossRef98
Paul Thistle, Rachel F. Spitzer, Richard H. Glazier, Richard Pilon, Gordon Arbess, Andrew Simor, Eleanor Boyle, Inam Chitsike, Tsungai Chipato, Maureen Gottesman, Michael Silverman. (2007) A Randomized, Double‐Blind, Placebo‐Controlled Trial of Combined Nevirapine and Zidovudine Compared with Nevirapine Alone in the Prevention of Perinatal Transmission of HIV in Zimbabwe. Clinical Infectious Diseases 44:1, 111-119
CrossRef99
Jintanat Ananworanich, Bernard Hirschel. (2007) Intermittent therapy for the treatment of chronic HIV infection. AIDS 21:2, 123-134
CrossRef100
Adriana S Duran, Marcelo H Losso, Horacio Salomón, D Robert Harris, Sandra Pampuro, Luis E Soto-Ramirez, Geraldo Duarte, Ricardo S de Souza, Jennifer S Read. (2007) Drug resistance among HIV-infected pregnant women receiving antiretrovirals for prophylaxis. AIDS 21:2, 199-205
CrossRef101
Tanarak Plipat, Thananda Naiwatanakul, Niramon Rattanasuporn, Orapan Sangwanloy, Pornsinee Amornwichet, Achara Teeraratkul, Kumnuan Ungchusak, Philip Mock, William Levine, Michelle S McConnell, RJ Simonds, Mary Culnane. (2007) Reduction in mother-to-child transmission of HIV in Thailand, 2001–2003: results from population-based surveillance in six provinces. AIDS 21:2, 145-151
CrossRef102
Athena P Kourtis, Francis K Lee, Elaine J Abrams, Denise J Jamieson, Marc Bulterys. (2006) Mother-to-child transmission of HIV-1: timing and implications for prevention. The Lancet Infectious Diseases 6:11, 726-732
CrossRef103
Francine Noel, Peter F Wright, Gyrlande Bois, Marie-Marcelle Deschamps, Patricia de Matteis, Rachelle Cassangnol, Maryse Thimothee, Katucia Celestin, Louise Vaz, John A Bradshaw, Emilio Brignoli, Yuwei Zhu, Warren D Johnson, Daniel Fitzgerald, Jean W Pape. (2006) Contribution of Bacterial Sepsis to Morbidity in Infants Born to HIV-Infected Haitian Mothers. JAIDS Journal of Acquired Immune Deficiency Syndromes 43:3, 313-319
CrossRef104
Lisa M. Frenkel, Jennifer McKernan, Phil V. Dinh, Deborah Goldman, Jane Hitti, D. Heather Watts, Ellen R. Cooper, Joan Dragavon, Robert W. Coombs. (2006) Short Communication: HIV Type 1 Zidovudine (ZDV) Resistance in Blood and Uterine Cervical Secretions of Pregnant Women. AIDS Research and Human Retroviruses 22:9, 870-873
CrossRef105
(2006) The mother-to-child HIV transmission epidemic in Europe: evolving in the East and established in the West. AIDS 20:10, 1419-1427
CrossRef106
Mary A. Vogler. (2006) Update: Preventing mother-to-child transmission of HIV. Current HIV/AIDS Reports 3:2, 59-65
CrossRef107
Rafik Samuel, Robert Bettiker, Byungse Suh. (2006) Antiretroviral therapy 2006: Pharmacology, applications, and special situations. Archives of Pharmacal Research 29:6, 431-458
CrossRef108
Roger L Shapiro, Ibou Thior, Peter B Gilbert, Shahin Lockman, Carolyn Wester, Laura M Smeaton, Lisa Stevens, S Jody Heymann, Thumbi Ndungʼu, Simani Gaseitsiwe, Vladimir Novitsky, Joseph Makhema, Stephen Lagakos, Max Essex. (2006) Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana. AIDS 20:9, 1281-1288
CrossRef109
Sada Soorapanth, Stephanie Sansom, Marc Bulterys, Mitchell Besser, Gerhard Theron, Mary Glenn Fowler. (2006) Cost-Effectiveness of HIV Rescreening During Late Pregnancy to Prevent Mother-to-Child HIV Transmission in South Africa and Other Resource-Limited Settings. JAIDS Journal of Acquired Immune Deficiency Syndromes 42:2, 213-221
CrossRef110
James A McIntyre. (2006) Controversies in the use of nevirapine for prevention of mother-to-child transmission of HIV. Expert Opinion on Pharmacotherapy 7:6, 677-685
CrossRef111
Sarah Palmer, Valerie Boltz, Frank Maldarelli, Mary Kearney, Elias K Halvas, Diane Rock, Judith Falloon, Richard T Davey, Robin L Dewar, Julia A Metcalf, John W Mellors, John M Coffin. (2006) Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. AIDS 20:5, 701-710
CrossRef112
James McIntyre. (2006) Strategies to prevent mother-to-child transmission of HIV. Current Opinion in Infectious Diseases 19:1, 33-38
CrossRef113
Heather E Vezina, Keith Henry, G D Ravindran, Anura V Kurpad, Tony D S Raj, Kathy Fox, Dennis Weller, Richard C Brundage, Winston Cavert, Henry H Balfour. (2006) A Randomized Crossover Study to Determine Bioequivalence of Generic and Brand Name Nevirapine, Zidovudine, and Lamivudine in HIV-Negative Women in India. JAIDS Journal of Acquired Immune Deficiency Syndromes 41:2, 131-136
CrossRef114
Marie-Louise Newell. (2006) Current issues in the prevention of mother-to-child transmission of HIV-1 infection. Transactions of the Royal Society of Tropical Medicine and Hygiene 100:1, 1-5
CrossRef115
D Heather Watts. (2006) Treating HIV During Pregnancy. Drug Safety 29:6, 467-490
CrossRef116
Carlo Giaquinto, Osvalda Rampon, Anita De Rossi. (2006) Antiretroviral Therapy for Prevention of Mother-to-Child HIV Transmission. Clinical Drug Investigation 26:11, 611-627
CrossRef117
Susan H Eshleman, Donald R Hoover, Shu Chen, Sarah E Hudelson, Laura A Guay, Anthony Mwatha, Susan A Fiscus, Francis Mmiro, Philippa Musoke, J Brooks Jackson, Newton Kumwenda, Taha Taha. (2005) Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS 19:18, 2167-2169
CrossRef118
James McIntyre. (2005) Prevention of mother-to-child transmission of HIV: treatment options. Expert Review of Anti-infective Therapy 3:6, 971-980
CrossRef119
Valériane Leroy, Charlotte Sakarovitch, Mario Cortina-Borja, James McIntyre, Hoosen Coovadia, Francois Dabis, Marie-Louise Newell. (2005) Is there a difference in the efficacy of peripartum antiretroviral regimens in reducing mother-to-child transmission of HIV in Africa?. AIDS 19:16, 1865-1875
CrossRef120
Benjamin H Chi, Lei Wang, Jennifer S Read, Muhsin Sheriff, Susan Fiscus, Elizabeth R Brown, Taha E Taha, Megan Valentine, Robert Goldenberg. (2005) Timing of maternal and neonatal dosing of nevirapine and the risk of mother-to-child transmission of HIV-1: HIVNET 024*. AIDS 19:16, 1857-1864
CrossRef121
Anna Coutsoudis, Hoosen M Coovadia, Marie-Louise Newell. (2005) Reply to ‘Mode of infant feeding and HIV infection in children in a program for prevention of mother-to-child transmission in Uganda’ by Magoni et al.. AIDS 19:15, 1718-1719
CrossRef122
Matthew F. Chersich, Glenda E. Gray. (2005) Progress and emerging challenges in preventing mother-to-child transmission. Current Infectious Disease Reports 7:5, 393-400
CrossRef123
Michael H Chung, James N Kiarie, Barbra A Richardson, Dara A Lehman, Julie Overbaugh, Grace C John-Stewart. (2005) Breast milk HIV-1 suppression and decreased transmission: a randomized trial comparing HIVNET 012 nevirapine versus short-course zidovudine. AIDS 19:13, 1415-1422
CrossRef124
Susan H Eshleman, Laura A Guay, Jing Wang, Anthony Mwatha, Elizabeth R Brown, Philippa Musoke, Francis Mmiro, J Brooks Jackson. (2005) Distinct Patterns of Emergence and Fading of K103N and Y181C in Women With Subtype A vs. D After Single-Dose Nevirapine. JAIDS Journal of Acquired Immune Deficiency Syndromes 40:1, 24-29
CrossRef125
James McIntyre. (2005) REVIEW: Preventing mother-to-child transmission of HIV: successes and challenges. BJOG: An International Journal of Obstetrics & Gynaecology 112:9, 1196-1203
CrossRef126
Glenda E Gray, Michael Urban, Matthew F Chersich, Carolyn Bolton, Ronelle van Niekerk, Avy Violari, Wendy Stevens, James A McIntyre. (2005) A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers. AIDS 19:12, 1289-1297
CrossRef127
Kristine Hopkins, Regina Maria Barbosa, Daniela Riva Knauth, Joseph E. Potter. (2005) The impact of health care providers on female sterilization among HIV-positive women in Brazil. Social Science & Medicine 61:3, 541-554
CrossRef128
D. Hawkins, M. Blott, P. Clayden, A. de Ruiter, G. Foster, C. Gilling-Smith, B. Gosrani, H. Lyall, D. Mercey, M-L. Newell, S. O'Shea, R. Smith, J. Sunderland, C. Wood, G. Taylor, . (2005) Guidelines for the management of HIV infection in pregnant women and the prevention of mother-to-child transmission of HIV. HIV Medicine 6:S2, 107-148
CrossRef129
Jack Moodley, Jens L Wennberg. (2005) HIV in pregnancy. Current Opinion in Obstetrics and Gynecology 17:2, 117-121
CrossRef130
Rebecca A Clark, Kathleen E Squires. (2005) Gender-specific considerations in the antiretroviral management of HIV-infected women. Expert Review of Anti-infective Therapy 3:2, 213-227
CrossRef131
C THORNE, M NEWELL. (2005) HIV, hepatitis and pregnancy. Women's Health Medicine 2:2, 40-43
CrossRef132
Vincent Idemyor. (2005) The 2004 International AIDS Conference and How to Globally Counter HIV/AIDS. HIV Clinical Trials 6:1, 43-49
CrossRef133
Erika Check. (2004) Activists and researchers rally behind AIDS drug for mothers. Nature 432:7020, 935-935
CrossRef134
(2004) Nevirapine plus Zidovudine to Prevent Mother-to-Child Transmission of HIV. New England Journal of Medicine 351:19, 2013-2015
Full Text135
Marie-Louise Newell, Claire Thorne. (2004) Antiretroviral therapy and mother-to-child transmission of HIV-1. Expert Review of Anti-infective Therapy 2:5, 717-732
CrossRef136
Jourdain, Gonzague, Ngo-Giang-Huong, Nicole, Le Coeur, Sophie, Bowonwatanuwong, Chureeratana, Kantipong, Pacharee, Leechanachai, Pranee, Ariyadej, Surabhon, Leenasirimakul, Prattana, Hammer, Scott, Lallemant, Marc, . (2004) Intrapartum Exposure to Nevirapine and Subsequent Maternal Responses to Nevirapine-Based Antiretroviral Therapy. New England Journal of Medicine 351:3, 229-240
Full Text137
Coovadia, Hoosen, . (2004) Antiretroviral Agents — How Best to Protect Infants from HIV and Save Their Mothers from AIDS. New England Journal of Medicine 351:3, 289-292
Full Text
- Letters
